×
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
NASDAQ:CNSP

CNS Pharmaceuticals Stock Forecast, Price & News

$0.27
+0.01 (+5.00%)
(As of 07/7/2022 12:18 PM ET)
Add
Compare
Today's Range
$0.27
$0.27
50-Day Range
$0.26
$0.35
52-Week Range
$0.25
$1.98
Volume
23,200 shs
Average Volume
1.06 million shs
Market Capitalization
$10.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

CNS Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
822.5% Upside
$2.50 Price Target
Short Interest
Healthy
0.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.78 out of 5 stars

Medical Sector

749th out of 1,433 stocks

Pharmaceutical Preparations Industry

376th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CNSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNS Pharmaceuticals logo

About CNS Pharmaceuticals (NASDAQ:CNSP) Stock

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNSP Stock News Headlines

CNS Pharmaceutical Wins Approval From Swiss
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNSP
Fax
N/A
Employees
3
Year Founded
N/A

Company Calendar

Last Earnings
8/12/2021
Today
7/07/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+815.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-14,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.24 per share

Miscellaneous

Free Float
36,589,000
Market Cap
$10.93 million
Optionable
Not Optionable
Beta
1.67














CNS Pharmaceuticals Frequently Asked Questions

Should I buy or sell CNS Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CNS Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CNS Pharmaceuticals stock.
View analyst ratings for CNS Pharmaceuticals
or view top-rated stocks.

What is CNS Pharmaceuticals' stock price forecast for 2022?

1 brokerages have issued 12 month target prices for CNS Pharmaceuticals' stock. Their CNSP stock forecasts range from $1.00 to $4.00. On average, they expect CNS Pharmaceuticals' share price to reach $2.50 in the next year. This suggests a possible upside of 815.8% from the stock's current price.
View analysts' price targets for CNS Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has CNS Pharmaceuticals' stock performed in 2022?

CNS Pharmaceuticals' stock was trading at $0.7024 on January 1st, 2022. Since then, CNSP stock has decreased by 61.1% and is now trading at $0.2730.
View the best growth stocks for 2022 here
.

When is CNS Pharmaceuticals' next earnings date?

CNS Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for CNS Pharmaceuticals
.

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) released its quarterly earnings results on Thursday, August, 12th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01.
View CNS Pharmaceuticals' earnings history
.

Who are CNS Pharmaceuticals' key executives?

CNS Pharmaceuticals' management team includes the following people:
  • Mr. John Michael Climaco Esq., J.D., Chairman, CEO & Pres (Age 53, Pay $648k)
  • Mr. Christopher S. Downs CPA, CTP, FP&A, Chief Financial Officer (Age 44, Pay $398k)
  • Dr. Sandra L. Silberman M.D., Ph.D., Chief Medical Officer (Age 67, Pay $228k)
  • Dr. Waldemar Priebe Ph.D., Founder & Chairman of the Scientific Advisory Board
  • Dr. Donald H. Picker Ph.D., Chief Science Officer (Age 76)

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Square (SQ).

When did CNS Pharmaceuticals IPO?

(CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.

What is CNS Pharmaceuticals' stock symbol?

CNS Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNSP."

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CNS Pharmaceuticals' stock price today?

One share of CNSP stock can currently be purchased for approximately $0.27.

How much money does CNS Pharmaceuticals make?

CNS Pharmaceuticals (NASDAQ:CNSP) has a market capitalization of $10.93 million. The company earns $-14,040,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does CNS Pharmaceuticals have?

CNS Pharmaceuticals employs 3 workers across the globe.

How can I contact CNS Pharmaceuticals?

CNS Pharmaceuticals' mailing address is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. The official website for CNS Pharmaceuticals is www.cnspharma.com. The company can be reached via phone at 800-946-9185 or via email at ir@cnspharma.com.

This page (NASDAQ:CNSP) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.